CLAIMS

1. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament for the treatment or prevention of a P-selectin mediated disorder and/or symptoms, wherein crizanlizumab or binding fragment thereof is first provided in a loading phase, during which the subject receives a first amount of crizanlizumab or binding fragment thereof over a given period of time, and then a further amount of crizanlizumab or binding fragment thereof provided in a maintenance phase, during which the subject receives a lower amount of the antibody or binding fragment thereof over a given period of time.

2. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament for the treatment or prevention of a P-selectin mediated disorder and/or symptoms according to claim 1, wherein the P-selectin-mediated disorder and/or symptoms is sickle cell pain crisis.

3. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament for the prevention of sickle cell pain crisis according to claim 2.

4. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament for the reduction of annual rate of sickle cell pain crises according to claim 2 or 3.

5. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to any one of the claims 2 to 4, wherein crizanlizumab or binding fragment thereof is provided to a subject at an amount of between 1 mg/kg to 20 mg/kg in one or more loading doses followed by a plurality of maintenance doses, wherein average time intervals between the maintenance doses are longer than average time intervals following the one or more loading doses, or wherein the concentration of the loading doses is higher than the concentration of the maintenance doses.

6. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to any one of the claims 1 to 5, wherein crizanlizumab or binding fragment thereof is provided to the subject by an intravenous route.

7. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to any one of the claims 1 to 6, wherein crizanlizumab or binding fragment thereof is provided to the subject in a loading dose of between 2.5 mg/kg to 7.5 mg/kg, or preferably 2.5 mg/kg to 5 mg/kg.

8. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to claim 7, wherein the loading dose is 5 mg/kg or 7.5 mg/kg.

9. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to any one of the claims 1 to 8, wherein crizanlizumab or binding fragment thereof is provided to the subject in a maintenance dose of between 2.5 mg/kg to 7.5 mg/kg, or preferably 2.5 mg/kg to 5 mg/kg.

10. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to claim 9, wherein the maintenance dose is 5 mg/kg or 7.5 mg/kg.

11. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to any one of the claims 1 to 10, wherein said loading dose and maintenance dose are equal, wherein time intervals between the maintenance doses are longer than time intervals between the loading doses.

12. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to any one the claims 1 to 10, wherein said loading dose is higher than said maintenance dose, wherein time intervals between the maintenance doses are equal with the time intervals between the loading doses.

13. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to any one of the claims 1 to 12, wherein crizanlizumab or binding fragment thereof is provided to the subject in two loading doses.

14. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to any one of the claims 1 to 13, wherein the time interval between the loading doses is 2 weeks +/- 3 days.

15. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to any one of the claims 1 to 14, wherein the time interval between the maintenance doses is 4 weeks +/- 3 days.

16. Use of crizanlizumab or a binding fragment thereof for the manufacture of a medicament for the prevention of a sickle cell pain crisis, wherein the antibody is first provided in a loading phase, during which the subject receives two loading doses of the antibody at an amount of between 2.5 mg/kg to 5 mg/kg or 2.5 mg/kg to 7.5 mg/kg and wherein the time interval between the two loading doses is 2 weeks +/-3 days, and then further provided in a maintenance phase, during which the subject receives a plurality of maintenance doses of the antibody at an amount of between 2.5 mg/kg to 5 mg/kg or 2.5 mg/kg to 7.5 mg/kg and wherein the time interval between the plurality of maintenance doses is 4 weeks +/-3 days.

17. Use of crizanlizumab or a binding fragment thereof for the manufacture of a medicament for the prevention of a sickle cell pain crisis according to claim 16, wherein the antibody is first provided in a loading phase, during which the subject receives two loading doses of the antibody at an amount of 5 mg/kg and wherein the time interval between the two loading doses is 2 weeks +/-3 days, and then further provided in a maintenance phase, during which the subject receives a plurality of maintenance doses of the antibody at an amount of 5 mg/kg and wherein the time interval between the plurality of maintenance doses is 4 weeks +/-3 days.

18. Use of crizanlizumab or a binding fragment thereof for the manufacture of a medicament for the prevention of a sickle cell pain crisis according to claim 16, wherein the antibody is first provided in a loading phase, during which the subject receives two loading doses of the antibody at an amount of 7.5 mg/kg and wherein the time interval between the two loading doses is 2 weeks +/-3 days, and then further provided in a maintenance phase,

during which the subject receives a plurality of maintenance doses of the antibody at an amount of 7.5 mg/kg and wherein the time interval between the plurality of maintenance doses is 4 weeks +/-3 days.

19. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to any one of the claims 1- 18 further in combination with hydroxyurea.

20. Use of crizanlizumab or binding fragment thereof for the manufacture of a medicament according to any one of the claims 16 to 19, wherein crizanlizumab or binding fragment thereof is provided to the subject by an intravenous route.

21. Use of crizanlizumab for the manufacture of a medicament for reducing the frequency of sickle cell-related vaso-occlusive crises in a subject in need thereof, wherein the first two doses of said antibody is provided 2 weeks +/-3 days apart followed by further doses provided every 4 weeks +/-3 days, wherein each dose is 5 mg/kg.

22. Use of crizanlizumab for the manufacture of a medicament for reducing the frequency of sickle cell-related vaso-occlusive crises in a subject in need thereof, wherein the first two doses of said antibody is provided 2 weeks +/-3 days apart followed by further doses provided every 4 weeks +/-3 days, wherein each dose is 7.5 mg/kg.

23. Use of crizanlizumab for the manufacture of a medicament according to claim 21 or 22, wherein the antibody is provided to the subject by an intravenous route.

24. Use of crizanlizumab for the manufacture of a medicament according to claim 23, wherein the antibody is provided over a delivery time of 30 minutes.

25. Use of crizanlizumab for the manufacture of a medicament according to any one of claims 21-24, wherein said doses are provided for a period of at least 3 months.

26. Use of crizanlizumab for the manufacture of a medicament according to any one of claims 21-25, wherein said doses are provided for a period of at least 12 months.

27. Use of crizanlizumab for the manufacture of a medicament according to any one of claims 21-26, wherein the annual rate of sickle cell pain crises is reduced by on average at least 30% as compared to the annual rate of sickle cell pain crises in the same patient had prior to receiving crizanlizumab treatment.

28. Use of crizanlizumab for the manufacture of a medicament according to any one of claims 21-27, wherein the annual rate of sickle cell pain crises is reduced by on average at least 30% up to 70% as compared to the annual rate of sickle cell pain crises in the same patient had prior to receiving crizanlizumab treatment.